UTHR Stock Analysis — United Therapeutics
Sector: Healthcare
AI Verdict
You're paying less than the sector average at 18.3x forward earnings, but with profits set to shrink, the moat around rare disease drugs needs to deliver new growth soon or the discount could persist.
Competitive Moat
United Therapeutics develops and commercializes treatments for pulmonary arterial hypertension and rare diseases, with a defensible position due to its portfolio of orphan drugs and regulatory exclusivity. The company’s focus on complex, hard-to-replicate therapies and established distribution relationships creates a barrier for generic competition.
Summary
The stock stands out for its rare disease drug portfolio and regulatory exclusivity, but faces a near-term earnings decline.
Where It Stands
UTHR trades at 18.3x next year's earnings, a discount to the healthcare median of 22x, but with analyst consensus calling for -9.0% EPS growth, the multiple is rising as earnings fall.
Key Metrics
- Trailing P/E: 16.7x
- Forward P/E: 18.3x
- Earnings Growth: -0.1%
- Revenue Growth: +0.1%
- 52-Week High: $609.35
- 52-Week Low: $272.12
Analyst Consensus
18 Buy · 4 Hold · 0 Sell (22 analysts)
Bull Case
With a trailing P/E of 16.7x, UTHR is cheaper than most healthcare peers, and its 5.9% revenue growth shows the current portfolio is still delivering top-line momentum.
Bear Case
Forward EPS is expected to shrink by -9.0%, so if the P/E reverts to the sector median of 22x only after growth returns, the stock could tread water or lose ground in the meantime.
Catalyst to Watch
Watch for clinical trial results or regulatory decisions on pipeline drugs—positive outcomes could reverse the -9.0% EPS growth outlook.